Rainmed Medical Limited (2297) AI Stock Analysis

• Market Cap: HK$406.39M
• Dividend Yield: N/A
• Average Volume (3M): 3.71M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.77
• Revenue Growth: -53.10%
• EPS Growth: 5.79%
• Country: HK
• Employees: 270
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.03
• Shares Outstanding: 1,401,358,800
• 10 Day Avg. Volume: 1,490,900
• 30 Day Avg. Volume: 3,709,666
• PEG Ratio: -1.99
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 4.58
• P/FCF Ratio: -1.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: HK$0.50 ▲(92.31% Upside)
• Action: Reiterated Date: 10/31/25
• Date: Action: Reiterated 10/31/25

The overall stock score is primarily impacted by poor financial performance, characterized by declining revenues, persistent losses, and cash flow issues. Technical analysis indicates bearish momentum, with the stock trading below key moving averages. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield, further weighing down the score.

Positive Factors

Strong Equity Position

A strong equity position indicates financial stability and low financial risk, providing a solid foundation for potential future growth and investment.

Low Leverage

Low leverage reduces financial risk and interest burden, allowing the company more flexibility to invest in growth opportunities without the pressure of high debt repayments.

Innovative Product Portfolio

An innovative product portfolio in medical technology positions the company well to capture market share in a growing industry focused on improving healthcare efficiencies and outcomes.

Negative Factors

Declining Revenues

Declining revenues indicate challenges in market demand or competitive positioning, which can impact long-term profitability and growth potential.

Negative Cash Flows

Negative cash flows highlight difficulties in generating cash from operations, which can constrain the company's ability to invest in growth or manage financial obligations.

Operational Inefficiencies

Negative EBIT and EBITDA margins suggest operational inefficiencies, which can hinder profitability and require strategic adjustments to improve cost management and operational effectiveness.

Rainmed Medical Limited Business Overview & Revenue Model

Company Description

Rainmed Medical Limited, a medical device company, focus on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microvascular resistance systems. The company offers FlashAngio caFFR System, a coronary angiography-derived fractional flow reserve measurement system, which calculates FFR values based on a three-dimensional model of the coronary arterial system restored from two angiograms and FlashAngio caIMR System, a non-invasive microcirculatory lesion diagnosis and treatment system. It is also involved in developing intelligent angiographic injection, flash robot vascular intervention navigation operation system, and flash renal denervation systems. The company was founded in 2014 and is headquartered in Suzhou, China.

How the Company Makes Money

Rainmed Medical Limited generates revenue primarily through the sale of its medical devices and diagnostic solutions. Its revenue model is centered around direct sales to healthcare institutions, which includes hospitals and clinics, as well as partnerships with distributors and healthcare providers. Key revenue streams include the sale of proprietary medical equipment, licensing agreements for its technology, and ongoing service contracts for maintenance and support of its products. Significant partnerships with healthcare organizations and participation in government health initiatives also contribute to its earnings, as they expand market reach and facilitate adoption of its innovative solutions.

Rainmed Medical Limited Financial Statement Overview

Summary

Rainmed Medical Limited is facing challenges with declining revenues and persistent losses, impacting profitability and cash flows. The balance sheet shows financial stability with a strong equity position but is offset by negative returns on equity. Cash flow issues persist, with zero operating and free cash flows in the latest period, raising concerns about liquidity and operational sustainability.

Income Statement

The company has faced declining revenues from 2022 to 2024, with a significant revenue decrease of 45.6% from 2023 to 2024. Gross profit margins have decreased, indicating pressure on profitability. The net profit margin remains negative, reflecting ongoing losses. The EBIT and EBITDA margins are also negative, showcasing operational inefficiencies.

Balance Sheet

The company has a strong equity position with an equity ratio of 87.9% in 2024, indicating financial stability. However, the return on equity remains negative due to continued net losses. The debt-to-equity ratio is low at 0.063, signaling low leverage and financial risk.

Cash Flow

The company reported zero operating and free cash flows in 2024, indicating cash flow management issues. Previously, in 2023, the free cash flow was negative, reflecting challenges in generating cash from operations. The lack of positive cash flow generation is a concern for future operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	23.36M	39.82M	73.22M	83.60M	81.20M	6.10M
Gross Profit	10.33M	23.87M	48.55M	69.82M	69.03M	5.26M
EBITDA	-62.34M	-82.98M	-93.54M	-1.33B	-623.97M	-148.23M
Net Income	-104.02M	-113.50M	-115.83M	-1.35B	-633.64M	-145.24M
Balance Sheet
Total Assets	504.25M	463.06M	573.31M	690.33M	640.19M	70.52M
Cash, Cash Equivalents and Short-Term Investments	200.75M	205.55M	335.28M	578.96M	559.14M	30.59M
Total Debt	33.80M	25.58M	20.00M	28.98M	1.38B	23.55M
Total Liabilities	96.95M	53.15M	53.30M	71.69M	1.41B	291.46M
Stockholders Equity	405.50M	407.00M	515.05M	618.64M	-774.48M	-220.93M
Cash Flow
Free Cash Flow	-80.60M	-138.10M	-235.27M	-141.04M	-103.95M	-1.76M
Operating Cash Flow	-43.11M	-84.31M	-124.29M	-111.22M	-72.83M	2.27M
Investing Cash Flow	-13.77M	6.31M	180.29M	-515.74M	-27.98M	8.69M
Financing Cash Flow	0.00	723.00K	-15.88M	120.73M	633.85M	9.53M

Rainmed Medical Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.26
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2297, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.28, and below the 200-day MA of 0.28, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 47.93 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2297.

Rainmed Medical Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6609	61 Neutral	HK$1.63B	13.30	3.84%	―	32.93%	―
2190	58 Neutral	HK$7.16B	12.82	4.99%	0.48%	35.01%	483.73%
2500	53 Neutral	HK$1.07B	-1.91	-26.80%	―	-8.56%	-14.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2297	45 Neutral	HK$406.39M	-1.99	-23.53%	―	-53.10%	5.79%
2160	43 Neutral	HK$4.07B	-218.71	0.22%	―	-4.38%	―
2216	41 Neutral	HK$708.51M	-4.03	-8.93%	―	-30.60%	28.61%